Immune Cell Modulations in Nordic FL Patients After Lenalidomide in the SAKK 35/10 Trial

Follicular lymphoma (FL) is although responsive to various therapies considered incurable. Rituximab is known to have improved outcome, which seems to be accentuated if combined with lenalidomide.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Sandra Lockmer, Åsa Jeppsson-Ahlberg, Birgitta Sander, Eva Kimby, Björn Wahlin Source Type: research